Skip to main content

Advertisement

Table 2 Characteristics of patients in the current fingolimod (CF) and current dimethyl fumarate (CDMF) groups

From: The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis

Characteristic, n (%) CF (N = 61) CDMF (N = 129)
MS medication before taking this therapy
 Copaxone (glatiramer acetate) 17 (27.9 %) 25 (19.4 %)
 Tysabri (natalizumab) 9 (14.8 %) 21 (16.3 %)
 No other med, this was first drug 9 (14.8 %) 14 (10.9 %)
 Tecfidera or Gilenya (Dimethyl Fumerate) 6 (9.8 %) 14 (10.9 %)
 Avonex (interferon beta1a) 6 (9.8 %) 11 (8.5 %)
 Rebif (interferon beta 1a) 5 (8.2 %) 24 (18.6 %)
 Betaseron (interferon beta1b) 5 (8.2 %) 4 (3.1 %)
 Other medicine not listed 2 (3.3 %) 1 (0.8 %)
 No other med, took break from treatment 1 (1.6 %) 12 (9.3 %)
 Aubagio (teriflunomide) 1 (1.6 %) 2 (1.6 %)
 Extavia (interferon beta 1b) 0 (0.0 %) 1 (0.8 %)
Reasons switched to current therapy
 Previous medication side effects
  Yes 33 (67.3 %) 45 (44.1 %)
  No 16 (32.7 %) 57 (55.9 %)
 Wanted to take oral treatment
  Yes 31 (63.3 %) 63 (61.8 %)
  No 18 (36.7 %) 39 (38.2 %)
 Previous medication lack of effectiveness
  Yes 19 (38.8 %) 32 (31.4 %)
  No 30 (61.2 %) 70 (68.6 %)
 Struggled to take previous medication as prescribed
  Yes 16 (32.7 %) 16 (15.7 %)
  No 33 (67.3 %) 86 (84.3 %)
 Concerns regarding safety of previous medication
  Yes 14 (28.6 %) 28 (27.5 %)
  No 35 (71.4 %) 74 (72.5 %)
 Another reason not listed
  Yes 9 (18.4 %) 25 (24.5 %)
  No 40 (81.6 %) 77 (75.5 %)
 Change in health status
  Yes 8 (16.3 %) 24 (23.5 %)
  No 41 (83.7 %) 78 (76.5 %)
 Financial reasons
  Yes 2 (4.1 %) 4 (3.9 %)
  No 47 (95.9 %) 98 (96.1 %)